UNITED THERAPEUTICS CORPORATION
NASDAQ: UTHR (United Therapeutics Corporation)
Last update: 6 hours ago584.10
-3.78 (-0.64%)
| Previous Close | 587.88 |
| Volume | 407,357 |
| Price / Earnings (Forward) | 18.81 |
| Price / Sales | 8.64 |
| Price / Book | 4.01 |
| 52 Weeks Range |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
News Mood
- United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
- SPDR S&P MidCap 400 ETF (MDY) Adds Glaukos and United Therapeutics on Wednesday
AIStockmoo Score
| Value 30% | 1.6 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Priced low for its earnings growth. info | |
| The price implies earnings growth of 18.7% a year; the business can fund about 15.0% a year. info | |
| Dearer than its usual valuation. info | |
| Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info | |
| Earns well above its cost of capital. Returns on capital rising. info | |
| Timing 30% | 2.9 |
| From our AI technical analysis of the chart. info | NA |
| Uptrend over the past year. Trading near its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | -0.1 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | 1.8 |
| Insiders net selling recently. Price is above where insiders sold. info | |
| Institutions net +7.87% of shares in their latest 13F filings: 399 holders increased, 466 decreased (quarter to 30 Sep 2026). info | |
| Short interest -10.8% from 31 Aug to 30 Oct 2026, 3.5 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum fading. info | |
| Price is between support and resistance. info | |
| Final Score | 1.96 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | United Therapeutics Corporation | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| UTHR | - | - | - | 4.01 |
| NBIX | - | - | - | 4.42 |
| HCM | - | - | - | 2.09 |
| VTRS | - | 2.34% | - | 1.75 |
| RDHL | - | - | - | 0.570 |
| ALVO | - | - | - | - |
Select this tab to load the latest available analysis.
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MAHON PAUL A | - | 565.72 | -8,300 | -4,695,476 |
| PATUSKY CHRISTOPHER | - | 582.46 | -1,210 | -704,777 |
| ROTHBLATT MARTINE A | - | 579.67 | -38,000 | -22,027,555 |
| Aggregate Net Quantity | -47,510 | |||
| Aggregate Net Value ($) | -27,427,808 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 577.31 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PATUSKY CHRISTOPHER | Director | 09 Nov 2026 | Sell (-) | 1,210 | 582.46 | 704,777 |
| PATUSKY CHRISTOPHER | Director | 09 Nov 2026 | Option execute | 1,210 | - | - |
| ROTHBLATT MARTINE A | Officer | 09 Nov 2026 | Automatic sell (-) | 7,886 | 582.46 | 4,593,280 |
| ROTHBLATT MARTINE A | Officer | 09 Nov 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 09 Nov 2026 | Automatic sell (-) | 1,614 | 582.46 | 940,090 |
| ROTHBLATT MARTINE A | Officer | 06 Nov 2026 | Automatic sell (-) | 9,500 | 562.02 | 5,339,190 |
| ROTHBLATT MARTINE A | Officer | 06 Nov 2026 | Option execute | 9,500 | - | - |
| MAHON PAUL A | Officer | 05 Nov 2026 | Automatic sell (-) | 8,300 | 565.72 | 4,695,476 |
| MAHON PAUL A | Officer | 05 Nov 2026 | Option execute | 8,300 | - | - |
| ROTHBLATT MARTINE A | Officer | 05 Nov 2026 | Automatic sell (-) | 7,540 | 565.72 | 4,265,529 |
| ROTHBLATT MARTINE A | Officer | 05 Nov 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 05 Nov 2026 | Automatic sell (-) | 1,960 | 565.72 | 1,108,811 |
| ROTHBLATT MARTINE A | Officer | 04 Nov 2026 | Automatic sell (-) | 7,777 | 608.49 | 4,732,227 |
| ROTHBLATT MARTINE A | Officer | 04 Nov 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 04 Nov 2026 | Automatic sell (-) | 1,723 | 608.49 | 1,048,428 |
| Show more | ||||||
Institutions
Institutional ownership: 115.13%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 399 | 6,403,654 |
| Decreased | 466 | 3,853,603 |
| New | 88 | 1,342,432 |
| Sold out | 122 | 508,438 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 1,837,654 | 3.5 |
| 15 Oct 2026 | 2,457,723 | 2.6 |
| 30 Sep 2026 | 3,596,948 | 3.6 |
| 15 Sep 2026 | 2,800,470 | 3.9 |
| 31 Aug 2026 | 2,059,685 | 4.8 |
| 14 Aug 2026 | 2,112,367 | 3.5 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory and clinical milestones at the UBS London Healthcare Conference. The company r… |
| 16 Nov 2026 | Yahoo Finance |
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
SGIOY vs. UTHR: Which Stock Is the Better Value Option? |
| 12 Nov 2026 | Yahoo Finance |
What iShares S&P Mid-Cap 400 Growth ETF (IJK) Bought: FTI Leads on Tuesday
The fund added $119.8 million in new buying across 245 positions, with TechnipFMC and United Therapeutics each accounting for $1.8 million. |
| 12 Nov 2026 | Yahoo Finance |
iShares Core S&P Mid-Cap (IJH) Adds TechnipFMC and United Therapeutics on Tuesday
The $125.52 billion fund bought $187.1 million of stock and sold almost nothing, lifting 380 positions. |
| 11 Nov 2026 | Yahoo Finance |
LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth. |
| 11 Nov 2026 | Yahoo Finance |
LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
Liquidia reports surging YUTREPIA sales, record October shipments and expanding PAH adoption amid post-settlement market changes and referral disruptions. |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Q3 Earnings Call Highlights
Liquidia (NASDAQ:LQDA) reported a 31% sequential increase in third-quarter YUTREPIA sales as the company sought to reassure investors that its pulmonary arterial hypertension business can continue growing following a patent settlement with United Therapeutics. YUTREPIA net product sales rose to $22… |
| 10 Nov 2026 | Yahoo Finance |
Liquidia Corporation Reports Third Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026October 2026 total patient shipments reached their highest monthly level since launchResolved all litigation with United Therapeutics through a global… |
| 09 Nov 2026 | Yahoo Finance |
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., November 09, 2026--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in… |
| 08 Nov 2026 | Yahoo Finance |
The 5 most interesting analyst questions from United Therapeutics’s Q3 2026 earnings call
United Therapeutics’ latest quarter saw revenue exceed Wall Street expectations, but a notable decline in operating margin and GAAP profit below consensus drove a negative market response. Management attributed revenue growth primarily to strong demand for Tyvaso, citing increased patient starts… |
| 06 Nov 2026 | Yahoo Finance |
SPDR S&P MidCap 400 ETF (MDY) Adds Glaukos and United Therapeutics on Wednesday
The fund bought $109.8 million of Glaukos as a new position and sold out of Okta for $238.4 million. |
| 05 Nov 2026 | Yahoo Finance |
United Therapeutics (UTHR) Stock May Be Undervalued After $2B Buyback Plan
United Therapeutics has seen its share price climb sharply in recent years, so the core question now is whether that move is backed up by the earnings the business is producing today. Over the past 5 years, United Therapeutics has delivered a 200.5% share price return, which puts real pressure on… |
| 05 Nov 2026 | Yahoo Finance |
Should Record Revenue Require Action From United Therapeutics Stock Investors?
United Therapeutics reported Q3 2026 revenue of US$832.5 million compared with US$799.5 million a year earlier, while net income and earnings per share were lower year on year as the company increased spending and absorbed mixed product trends. The Board authorized a US$2.0b share repurchase… |
| 04 Nov 2026 | Yahoo Finance |
What Is Drawing Attention To United Therapeutics (UTHR) Today?
United Therapeutics (UTHR) just released third quarter 2026 results, reporting revenue of US$832.5 million and diluted earnings per share of US$5.71, alongside the completion of a US$2.0 billion share repurchase authorization. The latest quarterly update, the fresh clearance to begin a… |
| 04 Nov 2026 | Yahoo Finance |
United Therapeutics Corporation Q3 2026 Earnings Call Summary
Moby summary of United Therapeutics Corporation's Q3 2026 earnings call… |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |